A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)
Stopped early · Phase 1/Phase 2
Conditions studied: Advanced Solid Tumors
In brief
The study will evaluate the safety, tolerability, and pharmacokinetics (PK) of MK-1088 in monotherapy and in combination with pembrolizumab in participants with advanced solid tumors who have not responded to conventional therapy. The effect of MK-1088 on tumor size will also be examined.
Key facts
- Study ID
- NCT05394350
- Run by
- Merck Sharp & Dohme LLC
- People needed
- 27
- Starts
- 2022-07-07
- Expected to finish
- 2023-09-07
- Last updated by the study team
- 2024-11-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Has a histologically- or cytologically-confirmed diagnosis of advanced/metastatic solid tumor by pathology report and have received, have been intolerant to, or have been ineligible for treatment known to confer clinical benefit
- For metastatic castrate-resistant prostate cancer (mCRPC) only: (1) Must have previously received docetaxel, prior treatment with one other chemotherapy is allowed as well as up to 2 second-generation hormonal manipulations and (2) have prostate cancer progression within 6 months before screening, as determined by the investigator
- If human immunodeficiency virus (HIV) positive, has well-controlled HIV on anti-retroviral therapy (ART)
You may not qualify if…
- Has had chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation) before the first dose of study intervention
- Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years
- Has clinically active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has an active infection requiring therapy
- Has a history of interstitial lung disease
- Has a history of (noninfectious) pneumonitis that required steroids or current pneumonitis
- Has an active autoimmune disease that has required systemic treatment in the past 2 years
- Has concurrent active Hepatitis B and Hepatitis C virus infection
- Has HIV with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Has not fully recovered from any effects of major surgery without significant detectable infection
- Has a history or current evidence of a gastrointestinal (GI) condition or impaired liver function or diseases that in the opinion of the investigator may significantly alter the absorption or metabolism of oral medications
- Has clinically significant cardiovascular disease within 12 months from first dose of study intervention, including New York Health Association (NYHA) Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability
- Has a corrected QT interval using Fridericia's Correction Formula (QTcF) >470 msec
- Has history of an allogeneic stem cell transplant or a solid organ transplant.
- Has received prior systemic anticancer therapy including investigational agents within 4 weeks before allocation
- Has received prior radiotherapy within 2 weeks of start of study intervention, or had radiation-related toxicities requiring corticosteroids
- Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
- Has a "superscan" bone scan
Where it is running
- University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0103) — Miami, Florida, United States
- Laura and Isaac Perlmutter Cancer Center ( Site 0102) — New York, New York, United States
- South Texas Accelerated Research Therapeutics (START) ( Site 0101) — San Antonio, Texas, United States
- Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0201) — Toronto, Ontario, Canada
- Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0 — Québec, Quebec, Canada
- Rigshospitalet ( Site 0500) — Copenhagen, Capital Region, Denmark
- Herlev and Gentofte Hospital ( Site 0501) — Copenhagen, Capital Region, Denmark
- Odense Universitetshospital ( Site 0502) — Odense, Region Syddanmark, Denmark
- Rambam Health Care Campus-Oncology Division ( Site 0300) — Haifa, Israel
- Hadassah Medical Center ( Site 0302) — Jerusalem, Israel
- Cantonal Hospital St.Gallen ( Site 0403) — Sankt Gallen, Canton of St. Gallen, Switzerland
- Ospedale Regionale Bellinzona e Valli ( Site 0400) — Bellinzona, Canton Ticino, Switzerland
- Kantonsspital Graubünden-Medizin ( Site 0402) — Chur, Kanton Graubünden, Switzerland
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.